A surface-bound form of human C1 esterase inhibitor improves xenograft rejection

Transplantation

Volumn 69, Issue 5, 2000, Pages 749-755

  Matsunami, Katsuyoshi ^a   Miyagawa, Shuji ^a   Yamada, Mako ^a   Yoshitatsu, Masao ^a   Shirakura, Ryota ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C1S INHIBITOR; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE PHOSPHODIESTERASE;

ARTICLE; COMPLEMENT INHIBITION; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITOR COMPLEX; ENZYME SPECIFICITY; GRAFT REJECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SEQUENCE HOMOLOGY; STRUCTURE ANALYSIS; SWINE;

EID: 0034654463     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-200003150-00013     Document Type: Article

References (41)

1. McCurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury [see comments]. Nat Med 1995; 1: 423.
2. Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection. Proc Natl Acad Sci USA 1994; 91: 11153.
3. Rosengard AM, Cary NR, Langford GA, Tucker AW, Wallwork J, White DJ. Tissue expression of human complement inhibitor, decay-accelerating factor, in transgenic pigs: a potential approach for preventing xenograft rejection. Transplantation 1995; 59: 1325.
4. Cozzi E, Langford GA, Richards A, et al. Expression of human decay accelerating factor in transgenic pigs. Transplant Proc 1994; 26: 1402.
5. Auchincloss H Jr., Sachs DH. Xenogeneic transplantation. Annu Rev Immunol 1998; 16: 433.
6. Mikata S, Miyagawa S, Iwata K, et al. Regulation of complement-mediated swine endothelial cell lysis by a surface-bound form of human C4b binding protein. Transplantation 1998; 65: 363.
7. Bock SC, Skriver K, Nielsen E, et al. Human C1 inhibitor: primary structure, cDNA cloning, and chromosomal localization. Biochemistry 1986; 25: 4292.
8. Ziccardi RJ. The first component of human complement (C1): activation and control. Springer Semin Immunopathol 1983; 6: 213.
9. Davis AEd. C1 inhibitor and hereditary angioneurotic edema. Annu Rev Immunol 1988; 6: 595.
10. Schmoeckel M, Bhatti FNK, Cozzi E, et al. Orthotopic heart transplantation in a transgenic pig-to-primate model. Transplantation 1998; 65: 1570.
11. Zaidi A, Schmoeckel M, Bhatti FNK, et al. Life-supporting pig-to-primate renal xenotransplantation using genetically modified donors. Transplantation 1998; 65: 1584.
12. Miyagawa S, Shirakura R, Iwata K, et al. Effects of transfected complement regulatory proteins, MCP, DAF, and MCP/DAF hybrid, on complement-mediated swine endothelial cell lysis. Transplantation 1994; 58: 834.
13. Niwa H, Yamamura K, Miyazaki J. Efficient selection for high expression transfectants with a novel eukaryotic vector. Gene 1991; 108: 193.
14. Laemmli UK, Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (London) 1970; 227: 680.
15. Davitz MA, Low MG, Nussenzweig V. Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC): selective modification of a complement regulatory protein. J Exp Med 1986; 163: 1150.
16. Iida K, Mornaghi R, Nussenzweig V. Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med 1982; 155: 1427.
17. Scatchard G. The attractions of proteins for small molecules and ions. Ann NY Acad Sci 1949; 51: 660.
18. Korzeniewski C, Callewaert DM. An enzyme-release assay for natural cytotoxicity. J Immunol Methods 1983; 64: 313.
19. Tenner AJ, Frank MM. Activator-bound C1 is less susceptible to inactivation by C1 inhibition than is fluid-phase C1. J Immunol 1986; 137: 625.
20. Dalmasso AP, Platt JL. Prevention of complement-mediated activation of xenogeneic endothelial cells in an in vitro model of xenograft hyperacute rejection by C1 inhibitor. Transplantation 1993; 56: 1171.
21. Heckl-Ostreicher B, Wosnik A, Kirschfink M. Protection of porcine endothelial cells from complement-mediated cytotoxicity by the human complement regulators CD59, C1 inhibitor, and soluble complement receptor type 1: analysis in a pig-to-human in vitro model relevant to hyperacute xenograft rejection. Transplantation 1996; 62: 1693.
22. Harpel PC, Cooper NR. Studies on human plasma C1 inactivater-enzyme interaction. J Clin Invest 1975; 55: 593.
23. Asch AS, Kinoshita T, Jaffe EA, Nussenzweig V. Decay-accelerating factor is present on cultured human umbilical vein endothelial cells. J Exp Med 1986; 163: 221.
24. Charreau B, Cassard A, Tesson L, et al. Protection of rat endothelial cells from primate complement-mediated lysis by expression of human CD59 and/or decay-accelerating factor. Transplantation 1994; 58: 1222.
25. Dalmasso AP, Vercellotti GM, Platt JL, Bach FH. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor: potential for prevention of xenograft hyperacute rejection. Transplantation 1991; 52: 530.
26. Friedl HP, Till GO, Trentz O, Ward PA. Roles of histamine, complement and xanthine oxidase in thermal injury of skin. Am J Pathol 1989; 135: 203.
27. Sandrin MS, Fodor W, Mouhtouris E, et al. Enzymatic remodeling of the carbohydrate surface of a xenogenic cell substantially reduces human antibody binding and complement-mediated cytolysis. Nature Med 1995; 1: 1261.
28. Tanemura M, Miyagawa S, Ihara Y, et al. Significant downregulation of the major swine xenoantigen by N-acetylglucosaminyltransferase III gene transfection. Biochem Biophys Res Commun 1997; 235: 359.
29. Tanemura M, Miyagawa S, Koyota S, et al. Reduction of the major swine xenoantigen, the alpha-galactosyl epitope by transfection of the α2,3-sialyltransferase gene. J Biol Chem 1998; 273: 16421.
30. Galili U. Anti-Gal antibody prevents xenotransplantation. Science and Medicine. 1998; 5: 28.
31. Tearle RG, Tange MJ, Zannettino Z, et al. The α-1,3-galactosyl-transferase knockout mouse. Transplantation 1996; 61: 3.
32. Gigli I, Mason JW, Colman RW, Austen KF. Interaction of plasma kallikrein with the C1 inhibitor. J Immunol 1970; 104: 574.
33. Schreiber AD, Kaplan AP, Austen KF. Inhibition by C1INH of Hagemann factor fragment activation of coagulation, fibrinolysis, and kinin generation. J Clin Invest 1973; 52: 1402.
34. Siddique Z, McPhaden AR, Whaley K. A single base deletion from the C1-inhibitor gene causes type I hereditary angiooedema. Hum Hered 1992; 42: 231.
35. Nielsen EW, Gran JT, Straume B, Mellby OJ, Johansen HT, Mollnes TE. Hereditary angio-oedema: new clinical observations and autoimmune screening, complement and kallikreinkinin analyses. J Intern Med 1996; 239: 119.
36. Platt JL. New direction for organ transplantation. Nature 1998; 392: 11.
37. Nissen MH, Roepstorff P, Thim L, Dunbar B, Fothergill JE. Limited proteolysis of beta 2-microglobulin at Lys-58 by complement component C1s. Eur J Biochem 1990; 189: 423.
38. Nissen MH, Bregenholt S, Nording JA, Claesson MH. C1-esterase inhibitor blocks T lymphocyte proliferation and cytotoxic T lymphocyte generation in vitro. Int Immunol 1998; 10: 167.
39. Jiang H, Pillai S. Complement regulatory proteins on the sperm surface: relevance to sperm motility. Am J Reprod Immunol 1998; 39: 243.
40. Bozas SE, Kirszbaum L, Sparrow RL, Walker ID. Several vascular complement inhibitors are present on human sperm. Biol Reprod 1993; 48: 503.
41. Vanderpuye OA, Labarrere CA, McIntyre JA. The complement system in human reproduction. Am J Reprod Immunol 1992; 27: 145.